Bengal Physician Journal

Register      Login

VOLUME 8 , ISSUE 3 ( September-December, 2021 ) > List of Articles

Original Article

Effect of Oncoxin, a Food Supplement, on Terminal-stage Hepatocellular Carcinoma Patients

Faysal Ahmed, Dulal Chandra Das, Sheikh Mohammad Noor-E-Alam, Ayub A Mamun

Keywords : Food supplement, Hepatocellular carcinoma, Oncoxin, Terminal stage

Citation Information : Ahmed F, Das DC, Noor-E-Alam SM, Mamun A A. Effect of Oncoxin, a Food Supplement, on Terminal-stage Hepatocellular Carcinoma Patients. Bengal Physician Journal 2021; 8 (3):63-66.

DOI: 10.5005/jp-journals-10070-7061

License: CC BY-NC 4.0

Published Online: 23-12-2021

Copyright Statement:  Copyright © 2021; The Author(s).


Background: Liver cancer is currently the second-most common cause of cancer-related deaths worldwide and hepatocellular carcinoma (HCC) accounts for more than 90% of liver cancers. Patients with terminal HCC are those presenting with very poor Eastern Cooperative Oncology Group (ECOG) Performance Status 3–4 with tumors beyond the transplantation threshold. Their management of terminal HCC is only palliative support. Oncoxin is a nutritional supplement that is used as an over-the-counter nutritional prophylaxis for cancers. Our aim was to evaluate the effect of Oncoxin in terminal HCC patients along with the best supportive care (BSC), comparing that to the terminal-stage HCC patient only treated with BSC to determine the survival outcome as well as performance status, assessed by the ECOG Performance Status Scale. Materials and methods: This was a randomized control trial conducted at the Hepatology Department, Bangabandhu Sheikh Mujib Medical University (BSMMU) from December 2019 to February 2021. A total of 60 patients were included (30 patients for Oncoxin with BSC and 30 patients for BSC only) and randomized into two groups. They were followed up for 3 months. Results: In this study, it was observed that at 60 days, eight (26.7%) patients survived in the Oncoxin group and one (3.3%) patient survived in the BSC group. The difference was statistically significant (p <0.05). However, the Oncoxin administration had no survival benefit at 30 and 90 days follow up. After 30 days of treatment, a comparison of ECOG Performance Status between groups showed that all 12 (100%) patients in the Oncoxin group were in grade 3, while in the BSC group, four (44.4%) patients were in grade 3 and five (55.6%) patients were in grade 4. These differences were statistically significant. Conclusion: The study shows that Oncoxin appears to increase the survival of some, but not all, patients with terminal-stage HCC. The improvement of ECOG Performance Status was also observed.

  1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136(5): p. 359–386. DOI: 10.1002/ijc.29210.
  2. Forman D, Bray F, Brewster DH, et al. Cancer Incidence in Five Continents Vol. X. IARC Scientific Publications No. 164. International Agency for Research on Cancer Lyon, France 2014.
  3. Jabeen S, Islam MJ, Talukder MH, et al. Pathoepidemiology of Cervical Cancer in National Institute of Cancer Research and Hospital of Bangladesh. Journal of Dhaka Medical College 2015;23(2): p.203–210. DOI: 10.3329/jdmc.v23i2.25392.
  4. Mahtab MA, Karim F, Foster G, et al. Prevalence and risk factors of asymptomatic hepatitis C virus infection in bangladesh. J Clin Exp Hepatol 2011;1(1): p.13–16. DOI: 10.1016/S0973-6883(11)60111-4. PMID: 25755305; PMCID: PMC3940088.
  5. Hussain SA, Sullivan R. Cancer control in Bangladesh. Jpn J Clin Oncol 2013;43(12): p. 1159–1169. DOI: 10.1093/jjco/hyt140. PMID: 24163419; PMCID: PMC3842101.
  6. Al-Mahtab M, Akbar SM, Khan MS, et al. Increased survival of patients with end-stage hepatocellular carcinoma due to intake of ONCOXIN®, a dietary supplement. Indian J Cancer 2015;52(3): p. 443–446. DOI: 10.4103/0019-509X.176699. PMID: 26905163.
  7. Kato H, Yoshida H, Taniguch H, et al. Cyberknife treatment for advanced or terminal stage hepatocellular carcinoma. World J Gastroenterol 2015;21(46): p. 13101–13112. DOI: 10.3748/wjg.v21.i46.13101. PMID: 26673627; PMCID: PMC4674729.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.